Adma Biologics Inc. (NASDAQ:ADMA)‘s stock had its “hold” rating reaffirmed by analysts at Maxim Group in a research report issued on Monday.

Separately, Raymond James Financial Inc. lowered shares of Adma Biologics from a “strong-buy” rating to a “market perform” rating in a research report on Monday, August 1st.

Shares of Adma Biologics (NASDAQ:ADMA) opened at 6.33 on Monday. The stock has a 50 day moving average price of $6.25 and a 200-day moving average price of $6.42. Adma Biologics has a 52 week low of $4.15 and a 52 week high of $9.65. The firm’s market capitalization is $81.57 million.

A number of institutional investors have recently added to or reduced their stakes in the company. Springbok Capital Management LLC raised its position in Adma Biologics by 10.0% in the first quarter. Springbok Capital Management LLC now owns 13,195 shares of the company’s stock worth $107,000 after buying an additional 1,195 shares in the last quarter. Vanguard Group Inc. raised its position in Adma Biologics by 0.8% in the second quarter. Vanguard Group Inc. now owns 120,959 shares of the company’s stock valued at $720,000 after buying an additional 1,000 shares in the last quarter. Spark Investment Management LLC raised its position in Adma Biologics by 126.8% in the second quarter. Spark Investment Management LLC now owns 31,300 shares of the company’s stock valued at $186,000 after buying an additional 17,500 shares in the last quarter. UBS Oconnor LLC raised its position in Adma Biologics by 111.3% in the second quarter. UBS Oconnor LLC now owns 71,174 shares of the company’s stock valued at $423,000 after buying an additional 37,497 shares in the last quarter. Finally, Guggenheim Capital LLC raised its position in Adma Biologics by 36.3% in the second quarter. Guggenheim Capital LLC now owns 29,747 shares of the company’s stock valued at $177,000 after buying an additional 7,929 shares in the last quarter. 74.00% of the stock is currently owned by institutional investors and hedge funds.

About Adma Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

5 Day Chart for NASDAQ:ADMA

Receive News & Stock Ratings for Adma Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adma Biologics Inc. and related stocks with our FREE daily email newsletter.